Table 1.
Pharmacokinetic parameters of PUE in plasma and in brain tissue homogenate of rats.
| Parameters | PUE (20 mg/kg) | PUE (20 mg/kg)+Borneol (25 mg/kg) | PUE (20 mg/kg)+α-asarone (25 mg/kg) |
|---|---|---|---|
| AUC0-12 (Brain) (ng/mL h) | 48.05 ± 8.54 | 64.80 ± 22.713** | 86.02 ± 7.927** |
| MRT0-12 (Brain) (h) | 5.19 ± 0.22 | 4.39 ± 0.337* | 4.64 ± 0.528* |
| t1/2z (Brain) (h) | 11.33 ± 4.07 | 5.62 ± 2.844* | 12.81 ± 5.64 |
| Tmax (Brain) (h) | 0.31 ± 0.13 | 0.54 ± 0.53 | 0.61 ± 0.52 |
| Cmax (Brain) (ng/mL) | 13.24 ± 4.28 | 21.82 ± 9.33 | 35.16 ± 12.442** |
| AUC0-12 (Plasma) (ng/mL h) | 938.29 ± 208.57 | 874.95 ± 159.34 | 1003.32 ± 185.60 |
| MRT0-12 (Plasma) (h) | 2.81 ± 0.78 | 3.36 ± 0.39 | 3.42 ± 0.19 |
| t1/2z (Plasma) (h) | 1.66 ± 0.59 | 4.31 ± 1.991** | 3.39 ± 0.824* |
| Tmax (Plasma) (h) | 0.38 ± 0.22 | 0.56 ± 0.49 | 0.85 ± 0.61 |
| Cmax (Plasma) (ng/mL) | 439.15 ± 137.02 | 367.99 ± 201.93 | 368.58 ± 260.71 |
*p < .05 compared with the control group PUE without borneol or α-asarone.**p < .01 compared with the control group PUE without borneol or α-asarone.